Here are three prudent steps to take. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. However, even from this limited vantage point, OCGN appears destined to fail. For priority reviews, the timeline for an approval decision is reduced to six months. The statistics support having long-term exposure to this asset class. quotes delayed at least 15 minutes, all others at least 20 minutes. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. This can prove to be a costly lesson to learn. Sign up below to get this incredible offer! While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. Pricing likely would be favorable, given the lack of alternative treatments. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. CFO Sanjay Subramanian said that there was "the potential for near-term revenue," depending on the EUA. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. Its worth emphasizing: Ocugen stock is a play with enormous risk. The FDA's decision not to issue EUA really wasn't all that surprising, though. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. The odds of Ocugen stock winding up at zero are material. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. How can we possibly evaluate a stock on a fundamental basis with that being reality? However, sometimes the optimism isn't justified. A $30 million market capitalization doesnt mean Ocugen has no chance. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. These options will be cheaper than owning the stock itself. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Type a symbol or company name. 2023 InvestorPlace Media, LLC. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Ocugen sold $25 million of stock in a private placement before the merger. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. These symbols will be available throughout the site during your session. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. The Motley Fool recommends Moderna Inc. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. What Is the Best EV Stock to Buy Now? 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. Ocugen isnt a promotional, fly-by-night penny stock. Keith Speights for There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. Type a symbol or company name. Type a symbol or company name. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. The Ocugen deal is a way to salvage some limited value. Thats the thing with these low-priced penny stocks. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! As of this writing, Vince Martin has no positions in any securities mentioned. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. Copyright 2023 InvestorPlace Media, LLC. However, I wont be around to find out. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. But just because a company does not have crippling debt doesnt mean its a buy. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. Investors were hopeful that the small drugmaker would be able to win U.S. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. Please check your download folder. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. The short answer is: everything. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. In that list, you can even include penny-stock trader. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. *Average returns of all recommendations since inception. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. This decision. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. Keith Speights has no position in any of the stocks mentioned. Nasdaq Not an offer or recommendation by Stocktwits. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. Maybe. Objective investors could have clearly seen then that there actually were significant reasons to be concerned. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. These symbols will be available throughout the site during your session. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. Copyright 2023 InvestorPlace Media, LLC. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. In November, Bharat Biotech began Phase 3 testing of Covaxin in India. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. Plus500. The stock had gained some traction after they announced the. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. It has real products. Sign up below to get this incredible offer! That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. 1125 N. Charles St, Baltimore, MD 21201. Ocugen. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Copyright Lorem ipsum dolor sit amet, consectetur adipiscing elit. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. The second is that the balance sheet still needs some help. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. How long might it take for Ocugen to win full FDA approval for Covaxin? But there is no question some big-name stocks performed better than others along the way. Keith Speights owns shares of Pfizer. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Making the world smarter, happier, and richer. But the allure of the space is that when a company wins, its shareholders win big. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. Can you feel the ground moving beneath your feet? It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. You canfollow Will on Twitterat @HealyWriting. Its certainly possible. Even before that point, the most promising candidates generally can find funding. All rights reserved. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. That doesnt mean success is guaranteed. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. Bharat Biotech has a history of successful vaccine commercialization in South Asia. See disclosure here. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. The Ocugen deal is a way to salvage some limited value. That said, for investors who understand the potential downside, there is an intriguing story here. Investors should worry about companies with no revenue even under the best of circumstances. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. Its all about choice. It's hard to say for sure. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. ET on Friday. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. You never know when they will suddenly go on a squeeze. It brings in no revenue. Do not expect a recovery in Ocugen stock. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. The potential synergies of such a union do not seem clear. What should investors do now? Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. The combined company has an agreement to sell the rights to NeoCart to privately held Medavate, leaving it reliant on Ocugens pipeline. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. If Ocugen goes up, you can still profit. Emergency Use . It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. Hold) without suggesting a price target. Most biotech companies have intriguing stories on paper; Ocugen is no different. Keith Speights for The company initiated its Phase 3 trial of OCU300 back in July 2018. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. I will concede this: The one great thing about the stock market is there is a style for everyone. The stock had gained some traction after they announced the Ocugen merger in April. That's not going to happen now. But it does mean something. The Motley Fool->. Create your Watchlist to save your favorite quotes on Nasdaq.com. Investors need to understand the risk profile here. But any success they find will be without me as a shareholder. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. The Motley Fool has a disclosure policy. The newly renamed Ocugen stock kept declining through year-end, but has managed to stage a bit of a rally in 2020, gaining 15% year-to-date. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. As of this writing, Matt did not hold a position in any of theaforementioned securities. Click here to see what Matt has up his sleeve now. Theres even room for more lines. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. While anything is possible, I would not anticipate a miracle here. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. At the time, Ocugen was left for dead. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." The Motley Fool->. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. Unfortunately for longs, OCGN is much closer to the worst of conditions. quotes delayed at least 15 minutes, all others at least 20 minutes. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. 1125 N. Charles St, Baltimore, MD 21201. 1125 N. Charles St, Baltimore, MD 21201. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. If they invent a miracle treatment for a condition, the money will find its way to the stock. Custom BMW. The median estimate. If they have solid financials, but their trials continually fail, they will likely not succeed. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. It has no treatments to offer the market. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Other than an emphasis on cell therapies, the companies had almost nothing in common. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. This requires no immediate effort on your part. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. The $25 million private placement executed before the merger brought in much-needed cash. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. Even at around 40 cents per share, I would consider Ocugen stock overvalued. First, the balance sheet is in at least decent shape. For now, though, what happens in India stays in India. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Type a symbol or company name. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? The average Ocugen stock price for the last 52 weeks is 2.10. OCGN does not even appear to have an apparent reason to exist. Maybe OCGN stock will be one of them again. Learn More. Do Not Sell My Personal Information (CA Residents Only). But if they do, Ocugen stock at the least looks like an intriguing bet. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. Investors were hopeful that the small drugmaker would be able to win U.S. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. All rights reserved. The Motley Fool has a disclosure policy. Do Not Sell My Personal Information (CA Residents Only). Part of the proceeds will be used to support its partnership with Bharat. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. Honestly, OCGN stock is unlikely to survive. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. The Motley Fool has no position in any of the stocks mentioned. Instead, this appears destined to join the long list of failed biotech startups. Theres even room for more lines. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Theres an opportunity here. So, what goes wrong? Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Investing is always a game of balancing risk and reward. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania.
Greenwich Township Police Department, Articles O